Mizuho Securities USA’s Jasper Therapeutics JSPR Stock Holding History

Mizuho Securities USA’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-65,513	Closed	-$6.49M	–	265
2021 Q2	$6.49M	Buy	65,513 +39,511	+152%	+$3.93M	0.53%	25
2021 Q1	$2.57M	Buy	26,002 +13,002	+100%	+$1.32M	0.25%	82
2020 Q4	$1.3M	Sell	13,000 -4,595	-26%	-$457K	0.08%	82
2020 Q3	$1.72M	Sell	17,595 -3,655	-17%	-$365K	0.12%	82
2020 Q2	$2.06M	Buy	21,250 +4,917	+30%	+$481K	0.14%	77
2020 Q1	$1.55M	Buy	+16,333	New	+$1.6M	0.23%	74

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Mizuho Securities USA's JSPR Position: Q3 2021 in Review

Mizuho Securities USA sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 65,513 shares — an estimated $6.49M sold.

Mizuho Securities USA first reported a position in JSPR in Q1 2020 and held it in 6 quarters. The position peaked at $6.49M in Q2 2021. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Mizuho Securities USA reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Mizuho Securities USA sold 65,513 Jasper Therapeutics shares in Q3 2021, an estimated $6.49M.
Mizuho Securities USA first reported a position in Jasper Therapeutics in Q1 2020 and held it in 6 quarters.
Mizuho Securities USA's Jasper Therapeutics position peaked at $6.49M in Q2 2021.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Mizuho Securities USA's 13F filing for Q3 2021, filed 28 Oct 2021.